Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Capricor Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 5 distinct art units, showing a fully distributed examination structure across the listed portfolio.
RAGHU, GANAPATHIRAM is the busiest examiner, with 1 pending matter. Counsel should coordinate scientific positions centrally while assigning matter-level responsibility for each examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAGHU, GANAPATHIRAM | 1 | 73.7% | +26.5% |
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
| GU, QINHUA | 1 | 76.2% | +27.1% |
| TICHY, JENNIFER M.H. | 1 | 64.6% | +34.4% |
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906464 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | TICHY, JENNIFER M.H. | 53d overdue |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | ZHU, JIANJIAN | 2d overdue |
| 18920959 | ARGINASE BEARING VESICLE COMPOSITION AND METHOD OF USE | RAGHU, GANAPATHIRAM | — |
| 18577642 | METHOD FOR SURFACE EXPRESSION OF MEMBRANE PROTEINS THAT HAVE A CYTOPLASMIC C-TERMINAL TAIL | SALVOZA, M FRANCO G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906464 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | TICHY, JENNIFER M.H. | 53d overdue |
| 18011041 | Extracellular Vesicles Engineered to Be Loaded with Distinct RNA Cargo for Improved Therapeutic Efficacy | GU, QINHUA | 38d overdue |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | ZHU, JIANJIAN | 2d overdue |
| 18920959 | ARGINASE BEARING VESICLE COMPOSITION AND METHOD OF USE | RAGHU, GANAPATHIRAM | — |
| 18577642 | METHOD FOR SURFACE EXPRESSION OF MEMBRANE PROTEINS THAT HAVE A CYTOPLASMIC C-TERMINAL TAIL | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1672 | 1 |
| 1633 | 1 |
| 1653 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920959 | ARGINASE BEARING VESICLE COMPOSITION AND METHOD OF USE | RAGHU, GANAPATHIRAM | 1652 | §102§112 | Non-Final OA | — | Pending | Oct 20, 2024 |
| 18577642 | METHOD FOR SURFACE EXPRESSION OF MEMBRANE PROTEINS THAT HAVE A CYTOPLASMIC C-TERMINAL TAIL | SALVOZA, M FRANCO G | 1672 | §103§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18011041 | Extracellular Vesicles Engineered to Be Loaded with Distinct RNA Cargo for Improved Therapeutic Efficacy | GU, QINHUA | 1633 | §103 | Final Rejection | 38d overdue | Pending | Dec 16, 2022 |
| 17906464 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | TICHY, JENNIFER M.H. | 1653 | §102§103 | Final Rejection | 53d overdue | Pending | Sep 15, 2022 |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | ZHU, JIANJIAN | 1631 | §103§112Other | Final Rejection | 2d overdue | Pending | Nov 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCapricor Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Ganapathiram Raghu has the most, with 1 of Capricor Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
